BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28054320)

  • 1. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.
    González-Cao M; Arance A; Piulats JM; Marquez-Rodas I; Manzano JL; Berrocal A; Crespo G; Rodriguez D; Perez-Ruiz E; Berciano M; Soria A; Castano AG; Espinosa E; Montagut C; Alonso L; Puertolas T; Aguado C; Royo MA; Blanco R; Rodríguez JF; Muñoz E; Mut P; Barron F; Martin-Algarra S;
    Clin Transl Oncol; 2017 Jun; 19(6):761-768. PubMed ID: 28054320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
    J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
    Liu FX; Ou W; Diede SJ; Whitman ED
    Medicine (Baltimore); 2019 Jul; 98(30):e16542. PubMed ID: 31348273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
    J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
    JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
    Cimminiello C; Indini A; Di Guardo L; Prisciandaro M; Randon G; Tolomio E; De Braud F; Del Vecchio M
    Melanoma Res; 2019 Jun; 29(3):289-294. PubMed ID: 30520799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
    Gangadhar TC; Hwu WJ; Postow MA; Hamid O; Daud A; Dronca R; Joseph R; O'Day SJ; Hodi FS; Pavlick AC; Kluger H; Oxborough RP; Yang A; Gazdoiu M; Kush DA; Ebbinghaus S; Salama AKS
    J Immunother; 2017; 40(9):334-340. PubMed ID: 29028788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
    Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
    Sanlorenzo M; Vujic I; Daud A; Algazi A; Gubens M; Luna SA; Lin K; Quaglino P; Rappersberger K; Ortiz-Urda S
    JAMA Dermatol; 2015 Nov; 151(11):1206-1212. PubMed ID: 26222619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
    Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
    Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
    Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
    Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
    Cowey CL; Scherrer E; Boyd M; Aguilar KM; Beeks A; Krepler C
    J Immunother; 2021 Jul-Aug 01; 44(6):224-233. PubMed ID: 33734142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint inhibition for advanced mucosal melanoma.
    Thierauf J; Veit JA; Hess J; Treiber N; Lisson C; Weissinger SE; Bommer M; Hoffmann TK
    Eur J Dermatol; 2017 Apr; 27(2):160-165. PubMed ID: 28174141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse.
    Lomax AJ; Beith J; Bhadri V; Boyer M; Grimison P; Horvath LG; Kao S; Tattersall M; Thomas D; McNeil C
    Intern Med J; 2016 Dec; 46(12):1392-1398. PubMed ID: 27554283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
    Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS
    Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
    Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
    Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
    Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.